Inventor · disambiguated record
George Hynd
Also filed as: HYND GEORGE
40 granted patents·27 pending applications·180 citations·filing 2003–2024
97Inventor score
Files withJANSSEN PHARMACEUTICA NV14ASTERAND UK LTD12CANCER RESEARCH TECH LTD11HYND GEORGE7C4X DISCOVERY LTD4
Top patents by PatentIndex Score
67 records- 0194US8685973B2Pyrimidine cyclohexyl glucocorticoid receptor modulatorsCLARK ROBIN·Filed 2012·Granted Apr 1, 2014·49 cites·15 claims
- 0292US11680068B2Compounds useful as RET inhibitorsCANCER RESEARCH TECH LTD·Filed 2022·Granted Jun 20, 2023·1 cites·14 claims
- 0391US8906917B2Pyrimidine cyclohexyl glucocorticoid receptor modulatorsCORCEPT THERAPEUTICS INC·Filed 2014·Granted Dec 9, 2014·15 cites·14 claims
- 0491US7326732B2EP2 receptor agonistsPHARMAGENE LAB LTD·Filed 2005·Granted Feb 5, 2008·18 cites·8 claims
- 0590US11352361B2Compounds useful as RET inhibitorsCANCER RESEARCH TECH LTD·Filed 2018·Granted Jun 7, 2022·3 cites·22 claims
- 0689US10954241B2Heterocyclic compounds as ret kinase inhibitorsCANCER RESEARCH TECH LTD·Filed 2017·Granted Mar 23, 2021·3 cites·29 claims
- 0789US9321736B2Pyrimidine cyclohexyl glucocorticoid receptor modulatorsCORCEPT THERAPEUTICS INC·Filed 2014·Granted Apr 26, 2016·11 cites·6 claims
- 0889US7803841B2EP2 receptor agonistsASTERAND UK LTD·Filed 2008·Granted Sep 28, 2010·11 cites·13 claims
- 0988US10844067B2Heterocyclic compounds as RET kinase inhibitorsCANCER RESEARCH TECH LTD·Filed 2017·Granted Nov 24, 2020·4 cites·27 claims
- 1087US11548896B2Heterocyclic compounds as RET kinase inhibitorsCANCER RESEARCH TECH LTD·Filed 2021·Granted Jan 10, 2023·1 cites·30 claims
- 1186US7662839B2EP2 receptor agonistsASTERAND UK LTD·Filed 2007·Granted Feb 16, 2010·7 cites·15 claims
- 1285US11661423B2Heterocyclic compounds as RET kinase inhibitorsCANCER RESEARCH TECH LTD·Filed 2020·Granted May 30, 2023·1 cites·24 claims
- 1385US2025236624A1Heterocyclic Compounds as RET Kinase InhibitorsCANCER RESEARCH TECH LTD·Filed 2024·Application pending·0 cites
- 1484US9643964B23-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancerJANSSEN PHARMACEUTICA NV·Filed 2014·Granted May 9, 2017·9 cites·15 claims
- 1584US7528157B2EP4 receptor antagonistsASTERAND UK LTD·Filed 2006·Granted May 5, 2009·3 cites·24 claims
- 1684US7507754B2EP4 receptor antagonistsASTERAND UK LTD·Filed 2007·Granted Mar 24, 2009·3 cites·41 claims
- 1782US2025243202A1Compounds Useful as RET InhibitorsCANCER RESEARCH TECH LTD·Filed 2024·Application pending·0 cites
- 1881US7196089B2EP4 receptor antagonistsASTERAND UK LTD·Filed 2004·Granted Mar 27, 2007·8 cites·30 claims
- 1981US2024132504A1Compounds Useful as RET InhibitorsCANCER RESEARCH TECH LTD·Filed 2023·Application pending·0 cites
- 2078US2023339954A1Heterocyclic Compounds as RET Kinase InhibitorsCANCER RESEARCH TECH LTD·Filed 2022·Application pending·0 cites
- 2177US7858640B2Quinolines and their therapeutic usePULMAGEN THERAPEUTICS ASTHMA LTD·Filed 2006·Granted Dec 28, 2010·10 cites·5 claims
- 2277US7417068B2EP4 receptor antagonistsASTERAND UK LTD·Filed 2004·Granted Aug 26, 2008·8 cites·15 claims
- 2376US2024116938A1Heterocyclic Compounds as RET Kinase InhibitorsCANCER RESEARCH TECH LTD·Filed 2023·Application pending·0 cites
- 2475US7569602B2Furan derivatives as EP4 receptor antagonistsASTERAND UK LTD·Filed 2004·Granted Aug 4, 2009·6 cites·13 claims
- 2574US8173812B2Quinolines and their therapeutic useMONTANA JOHN GARY·Filed 2008·Granted May 8, 2012·3 cites·8 claims
- 2673US8080567B2EP2 receptor agonistsOXFORD ALEXANDER WILLIAM·Filed 2006·Granted Dec 20, 2011·2 cites·21 claims
- 2772US12098148B2Therapeutic compoundsC4X DISCOVERY LTD·Filed 2019·Granted Sep 24, 2024·2 cites·32 claims
- 2868US7858644B2EP4 receptor antagonistsASTERAND UK LTD·Filed 2009·Granted Dec 28, 2010·0 cites·23 claims
- 2965US2025084075A1Therapeutic compoundsC4X DISCOVERY LTD·Filed 2024·Application pending·0 cites
- 3064US10822342B2Pyrazolopyrimidine derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Nov 3, 2020·0 cites·12 claims
- 3162US8394836B2Indoles and their therapeutic useHYND GEORGE·Filed 2008·Granted Mar 12, 2013·1 cites·4 claims
- 3261US2008306117A1Ep4 receptor antagonistsASTERAND UK LTD·Filed 2008·Application pending·0 cites
- 3359US11186589B2Cyanoindoline derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Nov 30, 2021·0 cites·20 claims
- 3456US7429607B25-HT2B receptor antagonistsASTERAND UK LTD·Filed 2003·Granted Sep 30, 2008·1 cites·16 claims
- 3554US10626089B2Quinoline derivative in crystal formGB001 INC·Filed 2019·Granted Apr 21, 2020·0 cites·17 claims
- 3653US2019119299A1Cyanoindoline derivatives as nik inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2017·Application pending·0 cites
- 3752US2010261760A1EP2 Receptor AgonistsASTERAND UK LTD·Filed 2010·Application pending·0 cites
- 3851US2023159511A1Tetrahydroisoquinoline compounds as nrf2 activatorsC4X DISCOVERY LTD·Filed 2021·Application pending·0 cites
- 3950US2023167084A1Tetrahydroisoquinoline compounds as nrf2 activatorsC4X DISCOVERY LTD·Filed 2021·Application pending·0 cites
- 4049US8394830B2Quinolines and their therapeutic useMONTANA JOHN GARY·Filed 2012·Granted Mar 12, 2013·0 cites·3 claims
- 4149US2019276405A1Crystal of quinoline derivativePULMAGEN THERAPEUTICS ASTHMA LTD·Filed 2017·Application pending·0 cites
- 4249US2023331719A1Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using SameOPTIKIRA LLC·Filed 2021·Application pending·0 cites
- 4348US11236084B2Substituted azaindoline derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2018·Granted Feb 1, 2022·0 cites·15 claims
- 4446US2011060026A1Indoles Active on CRTH2 ReceptorHYND GEORGE·Filed 2009·Application pending·0 cites
- 4545US10005773B21-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2014·Granted Jun 26, 2018·0 cites·29 claims
- 4645US9981963B23-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2014·Granted May 29, 2018·0 cites·20 claims
- 4745US2009221604A1Thiazole Compounds and Their Use as PGD2 AntagonistsHARRIS NEIL VICTOR·Filed 2006·Application pending·0 cites
- 4844US10221180B2Pyrazolopyrimidine derivatives as NIK inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2015·Granted Mar 5, 2019·0 cites·13 claims
- 4944US2022153734A1Pyrazolopyridine Compounds For IRE1 InhibitionOPTIKIRA LLC·Filed 2020·Application pending·0 cites
- 5042US2022194945A1Imidazolopyridine Compounds For IRE1 InhibitionOPTIKIRA LLC·Filed 2020·Application pending·0 cites
Showing the top 50 of 67 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →